ALSO NOTED: Elbion acquires drug candidates; Vanda looks to raise $96M;and much more...

> Belgium's Elbion NV has acquired some late-stage drug candidates from DrugAbuse Sciences. Two of the therapies are sustained-release forms of currently approved drug. Naltrexone Depot, an antagonist that blocks receptors in the brain and is used in the treatment of opiate and alcohol abuse, is expected to head into Phase III this year. Buprenorphine Depot, a sustained release buprenorphine indicated for the treatment of opiate addiction, is also included in the portfolio. No financial terms were disclosed. Release

> Shares of Vanda Pharmaceuticals were on the rise after it announced that it had priced an offering of 3.8 million shares at $27.29. The offering is designed to raise about $96 million. Vanda has been developing therapies for CNS diseases. Late last year Vanda confirmed positive data from a Phase III trial of its experimental insomnia drug, VEC-162. Report

> Bayer Innovation has licensed the rights to DelSiTech's drug delivery technology for fiber applications in the fields of wound care and certain other applications. Release

And Finally… A number of medical schools are prohibiting their students from taking advantage of the free lunches and other freebies offered by drug reps. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.